[Federal Register Volume 84, Number 37 (Monday, February 25, 2019)]
[Proposed Rules]
[Pages 5968-5969]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-03195]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 50, 312, and 812
[Docket No. FDA-2018-N-2727]
RIN 0910-AH52
Institutional Review Board Waiver or Alteration of Informed
Consent for Minimal Risk Clinical Investigations; Reopening of Comment
Period
AGENCY: Food and Drug Administration, HHS.
ACTION: Proposed rule; reopening of comment period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
reopening the comment period for the proposed rule that appeared in the
Federal Register of November 15, 2018. In the Federal Register of
December 20, 2018, the Agency extended the comment period until
February 13, 2019. The Agency is taking this action to reopen the
comment period to allow interested persons additional time to submit
comments due to technical issues with the Federal eRulemaking Portal
(https://www.regulations.gov) on February 13, 2019.
DATES: FDA is reopening the comment period on the proposed rule
published November 15, 2018 (83 FR 57378). Submit either electronic or
written comments by March 7, 2019.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before March 7, 2019. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of March 7, 2019. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2018-N-2727 for ``Institutional Review Board Waiver or Alteration
of Informed Consent for Minimal Risk Clinical Investigations.''
Received comments, those filed in a timely manner (see ADDRESSES), will
be placed in the docket and, except for those submitted as
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
[[Page 5969]]
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Janet Norden, Office of Good Clinical
Practice, Food and Drug Administration, 10903 New Hampshire Ave.,
Silver Spring, MD 20993-0002, 301-796-1127.
SUPPLEMENTARY INFORMATION: In the Federal Register of November 15, 2018
(83 FR 57378), FDA published a proposed rule with a 60-day comment
period to implement the statutory changes made to the Federal Food,
Drug, and Cosmetic Act by section 3024 of the 21st Century Cures Act
(Pub. L. 114-255) to allow for a waiver or alteration of informed
consent when a clinical investigation poses no more than minimal risk
to the human subject and includes appropriate safeguards to protect the
rights, safety, and welfare of human subjects. The proposed rule, if
finalized, would permit an institutional review board (IRB) to waive or
alter certain informed consent elements or to waive the requirement to
obtain informed consent, under limited conditions, for certain minimal
risk clinical investigations. Comments on the proposed rule will inform
FDA's rulemaking to establish regulations for IRB waiver or alteration
of informed consent for certain minimal risk clinical investigations.
The Agency received a request for a 60-day extension of the comment
period for the proposed rule. This request conveyed concern that the
60-day comment period did not allow sufficient time to develop a
meaningful or thoughtful response to the proposed rule. FDA considered
the request and in the Federal Register of December 20, 2018 (83 FR
65322), the Agency extended the comment period for the proposed rule
for 30 days, until February 13, 2019. The Agency believed that a 30-day
extension allowed adequate time for interested persons to submit
comments without significantly delaying rulemaking on these important
issues.
On February 13, 2019, the date that the comment period closed for
the proposed rule, the Federal eRulemaking Portal (https://www.regulations.gov) was unavailable to receive public comments from
5:35 p.m. until 7:40 a.m. on February 14, 2019. The Agency is aware
that interested persons attempted to submit comments during the period
of time that https://www.regulations.gov was unavailable. Therefore,
FDA is reopening the comment period for the proposed rule for 10 days,
until March 7, 2019 to allow additional time for interested persons to
submit comments.
Dated: February 20, 2019.
Lowell J. Schiller,
Acting Associate Commissioner for Policy.
[FR Doc. 2019-03195 Filed 2-22-19; 8:45 am]
BILLING CODE 4164-01-P